RIG-I helicase-independent pathway in Sendai virus-activated dendritic cells is critical for preventing lung metastasis of AT6.3 prostate cancer

Tomonori Kato, Yasuji Ueda, Hiroaki Kinoh, Yasuo Yoneyama, Akinao Matsunaga, Atsushi Komaru, Yui Harada, Hiroyoshi Suzuki, Akira Komiya, Satoko Shibata, Mamoru Hasegawa, Hideki Hayashi, Tomohiko Ichikawa, Yoshikazu Yonemitsu

Research output: Contribution to journalArticle

17 Citations (Scopus)


We recently demonstrated highly efficient antitumor immunity against dermal tumors of B16F10 murine melanoma with the use of dendritic cells (DCs) activated by replication-competent, as well as nontransmissible-type, recombinant Sendai viruses (rSeV), and proposed a new concept, "immunostimulatory virotherapy," for cancer immunotherapy. However, there has been little information on the efficacies of thismethod: 1) inmore clinically relevant situations including metastatic diseases, 2) on other tumor types and other animal species, and 3) on the related molecular/cellular mechanisms. In this study, therefore, we investigated the efficacy of vaccinating DCs activated by fusion gene-deleted nontransmissible rSeV on a rat model of lung metastasis using a highly malignant subline of Dunning R-3327 prostate cancer, AT6.3. rSeV/dF-green fluorescent protein (GFP)-activated bone marrow-derived DCs (rSeV/dF-GFP-DC), consistent with results previously observed in murine DCs. Vaccination of rSeV/dF-GFP-DC was highly effective at preventing lung metastasis after intravenous loading of R-3327 tumor cells, compared with the effects observed with immature DCs or lipopolysaccharide-activated DCs. Interestingly, neither CTL activity nor DC trafficking showed any apparent difference among groups. Notably, rSeV/dF-DCs expressing a dominantnegative mutant of retinoic acid-inducible gene I (RIG-I) (rSeV/dF-RIGIC-DC), an RNA helicase that recognizes the rSeV genome for inducing type I interferons, largely lost the expression of proinflammatory cytokines without any impairment of antitumor activity. These results indicate the essential role of RIG-I-independent signaling on antimetastatic effect induced by rSeV-activated DCs and may provide important insights to DC-based immunotherapy for advanced malignancies.

Original languageEnglish
Pages (from-to)906-914
Number of pages9
Issue number11
Publication statusPublished - Nov 2010


All Science Journal Classification (ASJC) codes

  • Cancer Research

Cite this